Cancer Research
CAR-T Based Immunotherapy for B-Cell Non-Hodgkin Lymphoma
A Phase I Single Arm, Open-Label Study to Evaluate the Safety of UF-KURE19 Cells in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
AGE: >18 years old
GENDER: All
GENDER: All
CONDITION: Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NHL)
TYPE: Interventional Treatment Study
HEALTHY PARTICIPANTS: No
HEALTHY PARTICIPANTS: No
Learn More About This Research Study
Please call 1-800-641-2422 for more information or complete the online form below.
Study Purpose
The purpose of this study is to determine if it is possible to treat your cancer with a new type of T-cell based immunotherapy, therapy that uses your immune system to treat the cancer.
Who Can Participate
Participants 18 years and older who have been diagnosed with relapsed or refractory non-Hodgkin lymphoma treated may be eligible for this study.
- StudyID20220867
- NCT05400109